- Home
- PTC vs GH Comparison
PTC vs GH Comparison
Compare PTC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTC | GH |
|---|---|---|
| Founded | 1985 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2B | 22.9B |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PTC | GH |
|---|---|---|
| Price | $196.37 | $156.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 26 |
| Target Price | ★ $201.27 | $200.88 |
| AVG Volume (30 Days) | ★ 2.2M | 2.0M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.87 | 6.74 |
| EPS | ★ 7.43 | N/A |
| Revenue | ★ $2,739,226,000.00 | $982,021,000.00 |
| Revenue This Year | $6.16 | $39.22 |
| Revenue Next Year | $8.11 | $35.02 |
| P/E Ratio | $26.36 | ★ N/A |
| Revenue Growth | 19.18 | ★ 32.88 |
| 52 Week Low | $108.50 | $74.55 |
| 52 Week High | $196.05 | $191.05 |
Technical Indicators
Market Signals| Indicator | PTC | GH |
|---|---|---|
| Relative Strength Index (RSI) | 76.34 | 42.03 |
| Support Level | $192.76 | $154.16 |
| Resistance Level | N/A | $177.55 |
| Average True Range (ATR) | 0.94 | 10.26 |
| MACD | -1.70 | -2.06 |
| Stochastic Oscillator | 96.14 | 41.04 |
Price Performance
Historical ComparisonAbout PTC PTC Inc.
PTC is a US-based global company that offers high-end computer-assisted design, product lifecycle management, and augmented reality solutions that industrial manufacturers commonly use on factory floors. Founded in 1985, PTC is a major player in parametric design and serves some of the world's most well-known equipment manufacturers, such as Caterpillar, Garmin, and Thermo Fisher.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.